Arbutus Biopharma Corp Proceeds from Sale of Restricted Investments
Arbutus Biopharma Corp (ABUS) reported Proceeds from Sale of Restricted Investments of $66.55 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfRestrictedInvestments · last filed 2020-11-05
- Arbutus Biopharma Corp proceeds from sale of restricted investments for the quarter ending 2020-09-30 was $19.60M, a 19.44% increase year-over-year.
- Arbutus Biopharma Corp proceeds from sale of restricted investments for the quarter ending 2020-06-30 was $24.98M, a 144.66% increase year-over-year.
- Arbutus Biopharma Corp proceeds from sale of restricted investments for the quarter ending 2020-03-31 was $21.97M, a 64.22% decline year-over-year.
- Arbutus Biopharma Corp proceeds from sale of restricted investments for the quarter ending 2019-09-30 was $16.41M, a 33.27% decline year-over-year.
| Period end | Proceeds from Sale of Restricted Investments 3 month | Proceeds from Sale of Restricted Investments 3 month as first filed | Proceeds from Sale of Restricted Investments 6 month | Proceeds from Sale of Restricted Investments 6 month as first filed | Proceeds from Sale of Restricted Investments 9 month |
|---|---|---|---|---|---|
| 2020-09-30 | $19.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $44.58M derived: sum of 2 quarters · filed 2020-11-05 | $66.55M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $24.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $46.95M 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $21.97M 10-Q · filed 2020-05-11 | ||||
| 2019-09-30 | $16.41M 10-Q · filed 2019-11-06 | $26.62M derived: sum of 2 quarters · filed 2019-11-06 | $87.67M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $10.21M 10-Q · filed 2019-08-05 | $71.75M 10-Q · filed 2020-08-07 | $71.27M 10-Q · filed 2019-08-05 | ||
| 2019-03-31 | $61.39M 10-Q · filed 2020-05-11 | $61.05M 10-Q · filed 2019-05-06 | |||
| 2018-09-30 | $24.59M 10-Q · filed 2019-11-06 | $39.99M derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $15.40M 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-06 | ||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |